Health Boards
Janssen announced today that STELARA® (ustekinumab) has been awarded the prestigious 2012 International Prix Galien Award at a ceremony in Lyon, France. The Prix Galien Award recognizes extraordinary efforts in biopharmaceutical and medical technology research and development by honoring biomedical advances impacting both individuals and public health in the past decade. The honor is acknowledgment of the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.
"It is a tremendous honor for Janssen to be recognized with the International Prix Galien Award for STELARA," said Jay P. Siegel, M.D., Chief Biotechnology Officer and Head, Global Regulatory Affairs, Janssen Research & Development, LLC. "We remain focused on bringing innovative medicines, like STELARA, to patients and health care professionals around the world."
STELARA is a human monoclonal antibody currently approved in more than 60 countries, including Canada, Europe, the United States, Brazil, Mexico, Australia and Japan, for the treatment of moderate to severe plaque psoriasis.
"STELARA exemplifies the convergence of science, technology and medicine," added Susan Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Janssen Research & Development, LLC. "We are proud of the difference that STELARA has and continues to make in the lives of patients battling moderate to severe plaque psoriasis, and are humbled to receive the International Prix Galien Award."
Considered the industry's highest accolade, the international Prix Galien Award is given every other year and selected from previous national contest Prix Galien winners. STELARA received the Prix Galien USA Best Biotechnology Product Award in 2011 and the Prix Galien Canada Innovative Product Award in 2010. Prix Galien was first established in 1970 by French pharmacist Roland Mehl, and the international award was inaugurated in 1990.
Source: prnewswire.com
Stelara (ustekinumab)
"It is a tremendous honor for Janssen to be recognized with the International Prix Galien Award for STELARA," said Jay P. Siegel, M.D., Chief Biotechnology Officer and Head, Global Regulatory Affairs, Janssen Research & Development, LLC. "We remain focused on bringing innovative medicines, like STELARA, to patients and health care professionals around the world."
STELARA is a human monoclonal antibody currently approved in more than 60 countries, including Canada, Europe, the United States, Brazil, Mexico, Australia and Japan, for the treatment of moderate to severe plaque psoriasis.
"STELARA exemplifies the convergence of science, technology and medicine," added Susan Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Janssen Research & Development, LLC. "We are proud of the difference that STELARA has and continues to make in the lives of patients battling moderate to severe plaque psoriasis, and are humbled to receive the International Prix Galien Award."
Considered the industry's highest accolade, the international Prix Galien Award is given every other year and selected from previous national contest Prix Galien winners. STELARA received the Prix Galien USA Best Biotechnology Product Award in 2011 and the Prix Galien Canada Innovative Product Award in 2010. Prix Galien was first established in 1970 by French pharmacist Roland Mehl, and the international award was inaugurated in 1990.
Source: prnewswire.com
Stelara (ustekinumab)